EA200501016A1 - Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила - Google Patents

Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила

Info

Publication number
EA200501016A1
EA200501016A1 EA200501016A EA200501016A EA200501016A1 EA 200501016 A1 EA200501016 A1 EA 200501016A1 EA 200501016 A EA200501016 A EA 200501016A EA 200501016 A EA200501016 A EA 200501016A EA 200501016 A1 EA200501016 A1 EA 200501016A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
modafinil
optical
modanfinil
entimers
Prior art date
Application number
EA200501016A
Other languages
English (en)
Other versions
EA009592B1 (ru
Inventor
Оливье Некеброк
Лоран Курвуазье
Стефани Граф
Жиль Серрюр
Жерар Кокрель
Себастьян Роз
Кристин Бессельевр
Франк Малле
Лангевельде Адриан Ян Ван
Original Assignee
Сефалон Франс
Организасьон Де Сентез Мондьяль Орсимонд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200501016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон Франс, Организасьон Де Сентез Мондьяль Орсимонд filed Critical Сефалон Франс
Publication of EA200501016A1 publication Critical patent/EA200501016A1/ru
Publication of EA009592B1 publication Critical patent/EA009592B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к способу получения кристаллических форм оптических энантиомеров модафинила, включающему в себя следующие этапы: i) растворение одного из оптических энантиомеров модафинила в растворителе, не являющемся этанолом; ii) кристаллизация энантиомера модафинила; iii) выделение полученной кристаллической формы энантиомера модафинила. Изобретение касается также способа получения оптических энантиомеров модафинила.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200501016A 2002-12-20 2003-12-18 Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила EA009592B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
PCT/FR2003/003799 WO2004060858A1 (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil

Publications (2)

Publication Number Publication Date
EA200501016A1 true EA200501016A1 (ru) 2005-12-29
EA009592B1 EA009592B1 (ru) 2008-02-28

Family

ID=32406320

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501016A EA009592B1 (ru) 2002-12-20 2003-12-18 Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила

Country Status (29)

Country Link
US (10) US7132570B2 (ru)
EP (6) EP2679576A3 (ru)
JP (2) JP4719471B2 (ru)
KR (1) KR101050565B1 (ru)
CN (5) CN101654423A (ru)
AR (1) AR042546A1 (ru)
AU (2) AU2003299349C1 (ru)
CA (2) CA2510096C (ru)
CL (2) CL2007002450A1 (ru)
CY (1) CY1114291T1 (ru)
DK (1) DK2343275T3 (ru)
EA (1) EA009592B1 (ru)
EG (1) EG24849A (ru)
ES (3) ES2425023T3 (ru)
FR (1) FR2849029B1 (ru)
HK (2) HK1192222A1 (ru)
IL (1) IL169205A (ru)
IS (1) IS7947A (ru)
MX (1) MXPA05006525A (ru)
MY (1) MY142926A (ru)
NO (1) NO335724B1 (ru)
NZ (2) NZ571235A (ru)
PL (1) PL377196A1 (ru)
PT (1) PT2343275E (ru)
SI (1) SI2343275T1 (ru)
TW (1) TWI344952B (ru)
UA (1) UA100964C2 (ru)
WO (1) WO2004060858A1 (ru)
ZA (1) ZA200504805B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077894A1 (en) * 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20070066996A1 (en) * 2003-03-17 2007-03-22 Katzman Daniel E Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
EP1603889A1 (en) * 2003-03-17 2005-12-14 Hetero Drugs Limited Novel crystalline forms of lamotrigine
EP1670753A4 (en) * 2003-09-04 2008-01-02 Cephalon Inc MODAFINIL COMPOSITIONS
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
WO2007103221A2 (en) * 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
CA2660565C (en) * 2006-08-14 2012-10-09 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080214862A1 (en) * 2006-12-06 2008-09-04 Ben-Zion Dolitzky Processes for preparing armodafinil intermediate
US20100010092A1 (en) * 2006-12-19 2010-01-14 Arless Ltd. Use of modafinil to treat restless leg syndrome
EP2155664A2 (en) * 2007-06-04 2010-02-24 Generics Ýuk¨Limited Novel process
WO2009024863A2 (en) * 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2292306B1 (en) * 2009-09-02 2013-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
EP2501674A2 (en) * 2009-11-19 2012-09-26 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
KR20120101588A (ko) * 2010-01-07 2012-09-13 비버스 인크. 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료
EP2649187B1 (en) 2010-12-08 2017-11-22 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) * 2014-06-24 2019-11-05 Paypal, Inc. Surfacing related content based on user interaction with currently presented content
US10841476B2 (en) * 2014-07-23 2020-11-17 Orcam Technologies Ltd. Wearable unit for selectively withholding actions based on recognized gestures
JPWO2016084585A1 (ja) * 2014-11-27 2017-09-14 株式会社ジーシー ワックスパターン表面処理剤、歯科用補綴物の製造方法
WO2017064723A1 (en) * 2015-10-12 2017-04-20 Natco Pharma Ltd An improved process for the preparation of armodafinil

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en) 1968-02-13 1970-07-08 Inst Noguchi Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr) 1988-02-10 1990-07-27 Lafon Labor 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2671349B1 (fr) 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CN1249932A (zh) 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
US20010036640A1 (en) 2000-04-25 2001-11-01 D'amico Kevin L. System and methods for the high throughput screening of polymorphs
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
DE10025756C2 (de) * 2000-05-25 2003-02-20 Cognis Deutschland Gmbh Lösungsvermittler
WO2005077894A1 (en) 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
KR20060024028A (ko) * 2000-07-27 2006-03-15 테바 파마슈티컬 인더스트리즈 리미티드 결정질의 순수한 모다피닐 및 이의 제조 방법
US6835307B2 (en) * 2000-08-04 2004-12-28 Battelle Memorial Institute Thermal water treatment
US6919378B2 (en) 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
WO2002041834A2 (en) 2000-11-03 2002-05-30 Teva Pharmaceutical Industries, Ltd. Atorvastatin hemi-calcium form vii
ATE357228T1 (de) 2001-05-25 2007-04-15 Cephalon Inc Feste pharmazeutische formulierung enthaltend modafinil
US20030124028A1 (en) 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
EP1466166B2 (en) 2002-01-15 2013-05-01 Avantium International B.V. Method for performing powder diffraction analysis
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CA2491908C (en) 2002-08-02 2011-09-13 Avantium International B.V. An assembly and method for performing parallel chemical experiments, in particular crystallisation experiments
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
WO2004052291A2 (en) 2002-12-06 2004-06-24 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
MXPA06002507A (es) 2003-09-04 2006-06-20 Cephalon Inc Composiciones de modafinil.
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP1802589B1 (en) 2004-10-13 2014-04-09 Pharmacia & Upjohn Company LLC Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
WO2007103221A2 (en) 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
EP2155664A2 (en) 2007-06-04 2010-02-24 Generics Ýuk¨Limited Novel process
WO2009024863A2 (en) 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en) 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

Also Published As

Publication number Publication date
US20060135621A1 (en) 2006-06-22
EP2679578A2 (fr) 2014-01-01
US20100048720A1 (en) 2010-02-25
CY1114291T1 (el) 2016-08-31
EP2679576A3 (fr) 2014-02-12
AU2003299349B2 (en) 2010-06-03
EP2679577A3 (fr) 2014-02-12
MXPA05006525A (es) 2005-12-05
CN101914044A (zh) 2010-12-15
BR0316916A (pt) 2005-10-18
EP2679578A3 (fr) 2014-03-19
EG24849A (en) 2010-10-27
UA100964C2 (ru) 2013-02-25
US20060241320A1 (en) 2006-10-26
BRPI0316916A8 (pt) 2015-09-22
PL377196A1 (pl) 2006-01-23
EP2676952A3 (fr) 2014-02-12
KR20050085847A (ko) 2005-08-29
US20100022653A1 (en) 2010-01-28
AU2010212462A1 (en) 2010-09-16
KR101050565B1 (ko) 2011-07-19
EP2343275A3 (fr) 2011-08-17
CN100540533C (zh) 2009-09-16
JP5497680B2 (ja) 2014-05-21
CL2007002450A1 (es) 2009-01-16
JP2006511588A (ja) 2006-04-06
CN101012189A (zh) 2007-08-08
TWI344952B (en) 2011-07-11
AU2003299349A8 (en) 2004-07-29
SI2343275T1 (sl) 2013-10-30
US20100048718A1 (en) 2010-02-25
ES2575018T3 (es) 2016-06-23
CN106065007A (zh) 2016-11-02
NZ571235A (en) 2010-01-29
NO20052912L (no) 2005-07-19
EP1572635A1 (fr) 2005-09-14
EP1572635B1 (fr) 2017-04-12
IL169205A (en) 2013-11-28
NO335724B1 (no) 2015-02-02
PT2343275E (pt) 2013-07-30
CN101654423A (zh) 2010-02-24
CA2724305A1 (fr) 2004-07-22
IS7947A (is) 2005-07-19
CN1751021A (zh) 2006-03-22
AR042546A1 (es) 2005-06-22
ZA200504805B (en) 2006-07-26
TW200419175A (en) 2004-10-01
CA2510096A1 (fr) 2004-07-22
HK1192222A1 (zh) 2014-08-15
CL2016002640A1 (es) 2017-03-24
US20090281193A1 (en) 2009-11-12
NO20052912D0 (no) 2005-06-15
DK2343275T3 (da) 2013-07-01
EA009592B1 (ru) 2008-02-28
EP2679577A2 (fr) 2014-01-01
US8729305B2 (en) 2014-05-20
EP2343275A2 (fr) 2011-07-13
US9382200B2 (en) 2016-07-05
US20130274521A1 (en) 2013-10-17
EP2676952A2 (fr) 2013-12-25
US20100048719A1 (en) 2010-02-25
CN101012189B (zh) 2013-03-13
JP2011102330A (ja) 2011-05-26
WO2004060858A1 (fr) 2004-07-22
ES2627808T3 (es) 2017-07-31
ES2425023T3 (es) 2013-10-10
US8975442B2 (en) 2015-03-10
AU2003299349C1 (en) 2011-01-20
FR2849029A1 (fr) 2004-06-25
US20090281192A1 (en) 2009-11-12
AU2003299349A1 (en) 2004-07-29
HK1225371A1 (zh) 2017-09-08
MY142926A (en) 2011-01-31
EP2343275B1 (fr) 2013-04-24
US7132570B2 (en) 2006-11-07
US20140031589A1 (en) 2014-01-30
JP4719471B2 (ja) 2011-07-06
NZ540733A (en) 2008-10-31
EP2679576A2 (fr) 2014-01-01
CA2510096C (fr) 2011-02-22
EP2679578B1 (fr) 2016-03-09
FR2849029B1 (fr) 2005-03-18

Similar Documents

Publication Publication Date Title
EA200501016A1 (ru) Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила
BR0313070A (pt) Métodos para preparação de um diastereÈmero desejado de uma tetraidro-beta-carbolina e para preparação de um composto
EA200400368A1 (ru) Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
EA200701738A1 (ru) Способ получения транс-1-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазина
EA200400682A1 (ru) Способ получения кристаллического имипенема
EA200301193A1 (ru) Оптическое разделение (1-бензил-4-метилпиперидин-3-ил)метиламина и его применение для получения производных пирроло 2,3-пиримидина в качестве ингибиторов протеинкиназы
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
EA200400082A1 (ru) Способ получения рацемического циталопрама и/или s- или r-циталопрама разделением смеси r- и s-циталопрама
EA200800107A1 (ru) Способ получения липида из клеток
EA200400809A1 (ru) Способ получения эсциталопрама
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
NO20062389L (no) Fremgangsmate for spray-storkning ved anvendelse av en ekstruder for fremstilling av multipartikkulaere azitromycinmaterialer
EA200100514A1 (ru) Способ получения метионина
EA200400487A1 (ru) Фармацевтическая композиция длительного высвобождения, содержащая метформин
PT1349828E (pt) Processo para a preparacao de isomeros de salutamol
BRPI0513881A (pt) processo para a preparação de compostos opticamente ativos
EA200300520A1 (ru) Способ получения кристаллического моногидрата n-формимидоилтиенамицина (моногидрата имипенема)
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
WO2006034812A3 (de) Verfahren zur herstellung von optisch aktiven 2-methylalkan-1-ols aus dem entsprechenden 2-methylalk-2-en-1-al, umfassend eine carbonylselektive reduktion, eine enantioselektive hydrierung und eine lipase-katalysierte, stereoselektive acylierung zwecks anreicherung des gewünschten enatiomers
ATE297933T1 (de) Ein verfahren zur herstellung von hochreinem cefpodoxim-proxetil
EA200301224A1 (ru) Способ получения имипенема
EA199900770A1 (ru) Способ получения фармацевтических соединений
ECSP056162A (es) Cristal derivado de benzimidazol y procedimiento para producirlo
DK1532146T3 (da) Fremgangsmåde til fremstilling af enantiomerer af indol-2,3-dion-3-oximderivater
EA200000279A1 (ru) Способ повышения оптической чистоты 2r-[1-гидрокси-1-трифторметил-3-циклопропилпропин-2-ил]-4-хлоранилина

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
HM1A Change in composition of inventors in a published eurasian application
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM